CN106233143B - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN106233143B
CN106233143B CN201580021401.8A CN201580021401A CN106233143B CN 106233143 B CN106233143 B CN 106233143B CN 201580021401 A CN201580021401 A CN 201580021401A CN 106233143 B CN106233143 B CN 106233143B
Authority
CN
China
Prior art keywords
cells
mrcc
tumor
positive
percentage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580021401.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106233143A (zh
Inventor
J-F·A·马丁尼
J·C·塔拉齐
J·A·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN106233143A publication Critical patent/CN106233143A/zh
Application granted granted Critical
Publication of CN106233143B publication Critical patent/CN106233143B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
CN201580021401.8A 2014-04-24 2015-04-16 癌症治疗 Expired - Fee Related CN106233143B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
US61/983,951 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (2)

Publication Number Publication Date
CN106233143A CN106233143A (zh) 2016-12-14
CN106233143B true CN106233143B (zh) 2020-01-21

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580021401.8A Expired - Fee Related CN106233143B (zh) 2014-04-24 2015-04-16 癌症治疗

Country Status (23)

Country Link
US (2) US20170184602A1 (enExample)
EP (1) EP3134119B1 (enExample)
JP (1) JP6603474B2 (enExample)
KR (1) KR101943177B1 (enExample)
CN (1) CN106233143B (enExample)
AR (1) AR100169A1 (enExample)
AU (3) AU2015249513A1 (enExample)
BR (1) BR112016024143A2 (enExample)
CA (1) CA2946362C (enExample)
CY (1) CY1120731T1 (enExample)
DK (1) DK3134119T3 (enExample)
ES (1) ES2691213T3 (enExample)
HU (1) HUE040167T2 (enExample)
IL (1) IL247859B (enExample)
MX (1) MX375794B (enExample)
PL (1) PL3134119T3 (enExample)
PT (1) PT3134119T (enExample)
RU (1) RU2651469C1 (enExample)
SG (1) SG11201607918TA (enExample)
SI (1) SI3134119T1 (enExample)
TR (1) TR201815682T4 (enExample)
TW (1) TWI568439B (enExample)
WO (1) WO2015162532A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
WO2020014666A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
KR102767594B1 (ko) * 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
US11409549B2 (en) 2018-10-15 2022-08-09 AIble Inc. Interface for generating models with customizable interface configurations
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US12656349B2 (en) 2019-10-17 2026-06-16 Board Of Regents, The University Of Texas System Measurement of bevacizumab-insensitive vascular endothelial growth factor-a
JP2025518482A (ja) * 2022-05-11 2025-06-17 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
CA3252723A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts USE OF A REP PROTEIN BMMF1 AS A DIAGNOSTIC MARKER FOR LUNG CANCER
EP4562058A4 (en) * 2022-07-28 2026-08-19 Univ Oklahoma BIOMARKERS, DIAGNOSTIC METHODS, TREATMENTS AND THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES AND DISORDERS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2013106765A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509613A (ja) 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CN101506351A (zh) * 2005-10-21 2009-08-12 拜尔健康护理有限责任公司 用于癌症预测和预后及监测癌症治疗的方法
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
BRPI0715062A2 (pt) * 2006-07-28 2013-06-04 Novartis Ag mÉtodos para determinar uma resposta de um indivÍduo mamÍfero que tem cÉlulas de tumor de melanoma ao tratamento com um agente inibidor de melanoma, para avaliar a eficÁcia de um agente inibidor de melanoma para tratar melanoma em um indivÍduo mamÍfero que tem melanoma, para determinar se um paciente deve continuar a receber tratamento com um agente inibidor de melanoma e para identificar agente que tÊm utilidade no tratamento de melanoma
EP2088863A2 (en) * 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
SG10201403896XA (en) * 2009-07-08 2014-10-30 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
KR101557545B1 (ko) * 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012068487A1 (en) * 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
AU2012318618B2 (en) * 2011-10-04 2017-01-12 Invivis Pharmaceuticals Inc. Methods and systems for identifying and treating anti-progestin sensitive tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2013106765A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Axitinib in Metastatic Renal Cell Carcinoma;Kriti Mittal et al;《Biol Ther》;20121016;第2卷(第5期);1-13 *
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Robert J Motzer et al;《Lancet Oncol》;20130416;第14卷;摘要 *
Tivozanib: Current status and future directions in the treatment of solid tumors;Sumanta K. Pal et al;《Expert Opin Investig Drugs.》;20121231;第21卷(第12期);1851–1859 *

Also Published As

Publication number Publication date
KR101943177B1 (ko) 2019-01-28
US20190331687A1 (en) 2019-10-31
CA2946362C (en) 2019-03-12
HUE040167T2 (hu) 2019-02-28
JP2015210268A (ja) 2015-11-24
BR112016024143A2 (pt) 2017-08-15
CY1120731T1 (el) 2019-12-11
AU2020200237A1 (en) 2020-02-06
HK1231561A1 (zh) 2017-12-22
AU2018203086A1 (en) 2018-05-24
SG11201607918TA (en) 2016-11-29
ES2691213T3 (es) 2018-11-26
MX2016013910A (es) 2017-01-11
JP6603474B2 (ja) 2019-11-06
DK3134119T3 (en) 2018-10-22
RU2651469C1 (ru) 2018-04-19
AR100169A1 (es) 2016-09-14
WO2015162532A1 (en) 2015-10-29
CN106233143A (zh) 2016-12-14
CA2946362A1 (en) 2015-10-29
TR201815682T4 (tr) 2018-11-21
MX375794B (es) 2025-03-07
PL3134119T3 (pl) 2018-12-31
TW201545747A (zh) 2015-12-16
AU2015249513A1 (en) 2016-10-06
SI3134119T1 (sl) 2018-11-30
KR20160134817A (ko) 2016-11-23
IL247859A0 (en) 2016-11-30
PT3134119T (pt) 2018-11-07
EP3134119A1 (en) 2017-03-01
IL247859B (en) 2020-07-30
EP3134119B1 (en) 2018-08-22
TWI568439B (zh) 2017-02-01
US20170184602A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
TWI568439B (zh) 癌症治療
US7736861B1 (en) Tivozanib response prediction
US9828635B2 (en) Predicting tumor response to anti-ERBB3 antibodies
WO2014089055A1 (en) Tivozanib response prediction
HK1231561B (en) Cancer treatment
Grincevičienė et al. Factors, associated with elevated concentration of soluble carbonic anhydrase IX in plasma of women with cervical dysplasia
HK1261117A1 (en) Predicting tumor response to anti-erbb3 antibodies
HK1200530B (en) Predicting tumor response to anti-erbb3 antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231561

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200121

CF01 Termination of patent right due to non-payment of annual fee